Oramed Pharmaceuticals Inc.

Director's Dealing • Nov 2, 2017

FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

By Regals Fund LP

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

* 1. Name and Address of Reporting Person Slager David Mark					2. Issuer Name and Ticker or Trading Symbol ORAMED ORMP ]			PHARMACEUTICALS	INC. [ X	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director Officer (give title		10% Owner Other (specify
(Last) (First) (Middle) 152 WEST 57TH STREET,					3. Date of Earliest Transaction (Month/Day/Year) 10/31/2017					below)	below)
9TH FLOOR					4. If Amendment, Date of Original Filed (Month/Day/Year)						6. Individual or Joint/Group Filing (Check Applicable Line)
(Street)											X Form filed by One Reporting Person
NEW YORK	NY	10019									Form filed by More than One Reporting Person
(City)	(State)	(Zip)
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
2. Transaction 1. Title of Security (Instr. 3) Date (Month/Day/Year)					2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)	(A) or		5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

	10/31/2017 16,892 A \$3.7656 1,316,328 I (1) M Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
Common Stock

Code V Amount

(D)

Price

(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code		V (A) (D)		Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Transaction(s) (Instr. 4)
Warrant (right to buy)	\$3.7656	10/31/2017		M			(2) 16,892		11/05/2012 11/05/2017	Common Stock		(3) 16,892 \$1.1796	0	I	By Regals Fund LP

Explanation of Responses:

1. Mr. Slager is Managing Member of the general partner of Regals Capital Management LP ("Regals Management"). Regals Management is the investment manager of Regals Fund LP (the "Fund"). The securities reported herein are held for the account of the Fund. Pursuant to Rule 16a-1(a)(4) under the Act, Mr. Slager disclaims beneficial ownership in the securities owned by the Fund except to the extent, if any, of his pecuniary interest therein.

2. The number of shares underlying such warrant and the applicable exercise price reflect a one-for-twelve reverse stock split effected by the issuer on January 22, 2013.

3. The shares and warrants were purchased as "units" at a price per unit of \$4.44 in connection with the Issuer's 2012 private placement. The consideration was allocated to the shares and warrants based on relative fair value. The value allocated to the warrants was estimated by using the Black Scholes option-pricing model.

/s/ David Slager 11/01/2017

** Signature of Reporting Person Date

Transaction(s) (Instr. 3 and 4)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.